Author

David Lanfear

Henry Ford Hospital - Cited by 6,743 - heart - genetics

Biography

Dr. David Lanfear is a cardiologist in Detroit, MI and is affiliated with Henry Ford Hospital. He received his medical degree from University of Michigan Medical School and has been in practice 19 years. He specializes in heart failure & transplantation and is experienced in echocardiography, cardiac critical care, heart failure and transplantation, vad management, and pharmacogenetics.
Title
Cited by
Year
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
JA Spertus, MC Birmingham, M Nassif, CV Damaraju, A Abbate, J Butler, ...Nature medicine 28 (4), 809-813, 2022202
84
2022
Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF
JR Teerlink, R Diaz, GM Felker, JJV McMurray, M Metra, SD Solomon, ...Journal of the American College of Cardiology 78 (2), 97-108, 2021202
72
2021
Effect of a hospital and postdischarge quality improvement intervention on clinical outcomes and quality of care for patients with heart failure with reduced ejection fraction …
AD DeVore, BB Granger, GC Fonarow, HR Al-Khalidi, NM Albert, ...Jama 326 (4), 314-323, 2021202
51
2021
Functional dynamic genetic effects on gene regulation are specific to particular cell types and environmental conditions
AS Findley, A Monziani, AL Richards, K Rhodes, MC Ward, CA Kalita, ...Elife 10, e67077, 2021202
32
2021
Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF
S Selvaraj, Z Fu, P Jones, LC Kwee, SL Windsor, O Ilkayeva, CB Newgard, ...Circulation 146 (11), 808-818, 2022202
21
2022
Prediction of survival after implantation of a fully magnetically levitated left ventricular assist device
MR Mehra, A Nayak, AA Morris, DE Lanfear, H Nemeh, S Desai, A Bansal, ...Heart Failure 10 (), 948-959, 2022202
12
2022
Plasma proteomic profile predicts survival in heart failure with reduced ejection fraction
H Gui, R She, J Luzum, J Li, TD Bryson, Y Pinto, HN Sabbah, LK Williams, ...Circulation: Genomic and Precision Medicine 14 (3), e003140, 2021202
7
2021
Racial inequities in Access to Ventricular assist device and transplant persist after consideration for preferences for care: a Report from the REVIVAL study
TM Cascino, MM Colvin, DE Lanfear, B Richards, S Khalatbari, DL Mann, ...Circulation: Heart Failure 16 (1), e00975, 2023202
4
2023
Aldehyde dehydrogenase 2 activator augments the beneficial effects of empagliflozin in mice with diabetes-associated HFpEF
G Pan, B Roy, S Giri, DE Lanfear, RA Thandavarayan, A Guha, PA Ortiz, ...International Journal of Molecular Sciences 23 (18), 1039, 2022202
4
2022
Frailty Measures of Patient-reported Activity and Fatigue May Predict 1-year Outcomes in Ambulatory Advanced Heart Failure: A Report From the REVIVAL Registry
A Lala, P Shah, S Khalatbari, M Yosef, MM Mountis, SW Robinson, ...Journal of cardiac failure 28 (5), 765-774, 2022202
3
2022
The genomics of heart failure: design and rationale of the HERMES consortium
RT Lumbers, S Shah, H Lin, T Czuba, A Henry, DI Swerdlow, A Mälarstig, ...ESC heart failure 8 (6), 551-5541, 2021202
3
2021
Health System–Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial
BB Granger, LA Kaltenbach, GC Fonarow, LA Allen, DE Lanfear, ...Journal of Cardiac Failure 8 (8), 1355-1361, 0
2
2022
The Canagliflozin Impact On Health Status, Quality Of Life And Functional Status In Heart Failure (CHIEF-HF) clinical trial
J Spertus, M Birmingham, CV Damaraju, A Abbate, J Butler, JL Januzzi Jr, ...CIRCULATION 144 (5), E57-E57, 010
2
2021
The Association of Digital Health Application Use With Heart Failure Care and Outcomes: Insights From CONNECT-HF
VN Rao, LA Kaltenbach, BB Granger, GC Fonarow, HR Al-Khalidi, ...Journal of cardiac failure 8 (10), 1487-1496, 0
2
2022
BNP and precision medicine: tip of an iceberg
DE Lanfear, JA LuzumBasic to Translational Science 6 (6), 505-506, 010
2
2021
Myosin-related dilated cardiomyopathy: another elephant emerges from darkness
DE Lanfear, N RezaJournal of the American College of Cardiology 80 (15), 146-1464, 0
2
2022
Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients with HFrEF: Results from the CONNECT-HF Trial.
BB Granger, LA Kaltenbach, GC Fonarow, LA Allen, DE Lanfear, ...Journal of Cardiac Failure, 2022202
1
2022
Predicting death from COVID-19 using pre-existing conditions: implications for vaccination triage
Predicting death from COVID-9 using pre-existing conditions: implications for vaccination triageS Xiao, N Sahasrabudhe, S Hochstadt, W Cabral, S Simons, M Yang, ...BMJ Open Respiratory Research 8 (), e0006, 20220
1
2021
Omecamtiv mecarbil in Black patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF
DE Lanfear, JN Njoroge, KF Adams, I Anand, JC Fang, F Ramires, ...Heart Failure (5), 569-579, 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=rGtMom4AAAAJ&hl=en

Cited by
Citations 6743
h-index 46
i10-index 111
Recommended Journals
Open Access Journals